Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Cancer Research
|
December 3, 2015
The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia
Adele Baker, Gareth P Gregory, Inge Verbrugge, et al.
Neuro-Oncology Advances
|
June 27, 2025
Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI
Jack O'Shaughnessy, Arina Martynchyk, Sze Ting Lee, et al.
Internal Medicine Journal
|
June 17, 2024
Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance
Masa Lasica, Mary A Anderson, Alex Boussioutas, et al.
Blood
|
December 1, 2020
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas
Scott Boiko, Theresa Proia, Maryann San Martin, et al.
Molecular Cancer Therapeutics
|
July 14, 2016
BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members
Simon J Hogg, Andrea Newbold, Stephin J Vervoort, et al.
Blood Advances
|
March 22, 2023
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
Maciej Tatarczuch, Mark Waltham, Jake Shortt, et al.
Haematologica
|
September 25, 2025
Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study
Eliza Chung, Luke Wang, Cameron Wellard, et al.
Blood Advances
|
January 18, 2025
Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review
Luke Wang, Eliza Chung, Cameron Wellard, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 9, 2024
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial
Matthew Matasar, Nancy L Bartlett, Mazyar Shadman, et al.
British Journal of Haematology
|
June 26, 2019
Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance
Joel C Wight, Mimi Yue, Colm Keane, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Cancer Research
|
December 3, 2015
The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia
Adele Baker, Gareth P Gregory, Inge Verbrugge, et al.
Neuro-Oncology Advances
|
June 27, 2025
Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI
Jack O'Shaughnessy, Arina Martynchyk, Sze Ting Lee, et al.
Internal Medicine Journal
|
June 17, 2024
Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance
Masa Lasica, Mary A Anderson, Alex Boussioutas, et al.
Blood
|
December 1, 2020
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas
Scott Boiko, Theresa Proia, Maryann San Martin, et al.
Molecular Cancer Therapeutics
|
July 14, 2016
BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members
Simon J Hogg, Andrea Newbold, Stephin J Vervoort, et al.
Blood Advances
|
March 22, 2023
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
Maciej Tatarczuch, Mark Waltham, Jake Shortt, et al.
Haematologica
|
September 25, 2025
Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study
Eliza Chung, Luke Wang, Cameron Wellard, et al.
Blood Advances
|
January 18, 2025
Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review
Luke Wang, Eliza Chung, Cameron Wellard, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 9, 2024
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial
Matthew Matasar, Nancy L Bartlett, Mazyar Shadman, et al.
British Journal of Haematology
|
June 26, 2019
Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance
Joel C Wight, Mimi Yue, Colm Keane, et al.
Page
of 4